DBV Technologies Advances Peanut Allergy Treatment, Plans BLA Submission in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Should l Buy DBVT?
Source: Benzinga
- Clinical Breakthrough: DBV Technologies announced positive topline results from the Phase 3 VITESSE trial of its VIASKIN® Peanut patch in December 2025, achieving a significant treatment effect with 46.6% responders compared to 14.8% in the placebo group, marking a major advancement in peanut allergy treatment.
- Accelerated Regulatory Path: The trial's success has led to alignment with the FDA on safety data, with plans for a Biologics License Application (BLA) submission in H1 2026, providing a safe and convenient non-invasive treatment option for peanut allergy patients, addressing a critical market need.
- Financial Performance: Despite generating $2.38 million in revenue last quarter, DBV reported a loss of $28.44 million, indicating the need for improved financial health in the rapidly growing allergy treatment market, while its high valuation and debt levels raise investor concerns.
- Leadership Enhancements: Recent appointments of a new Chief Commercial Officer and board members strengthen DBV's execution capabilities to navigate regulatory milestones and prepare for a potential U.S. launch, showcasing the company's strong potential to transition from clinical success to commercial impact.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.690
Low
40.00
Averages
46.40
High
51.00
Current: 21.690
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies has secured €166.7 million through the full exercise of ABSA and BS warrants, ensuring sufficient operational funding for the next 12 months to support the commercial readiness of the VIASKIN® Peanut patch.
- Equity Dilution Impact: The financing resulted in the issuance of 59,657,507 new shares, which is expected to dilute existing shareholders' ownership from 1% to 0.78%, impacting equity but providing necessary funding for future growth.
- Market Entry Plans: The proceeds will be utilized for a potential Biologics License Application (BLA) and the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new allergy treatment options for children aged 4 to 7, addressing significant market needs.
- Future Outlook: If all outstanding pre-funded warrants are exercised, total financing could reach approximately €284.5 million, further enhancing the company's competitive position in the food allergy treatment sector.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies has secured €166.7 million through the full exercise of ABSA and BS warrants, ensuring sufficient operational funding for the next 12 months to support the commercial readiness of the VIASKIN® Peanut patch.
- Equity Dilution Impact: The financing resulted in the issuance of 59,657,507 new shares, which is expected to dilute existing shareholders' ownership from 1% to 0.78%, impacting equity but providing necessary funding for future growth.
- Market Entry Plans: The proceeds will be utilized for a potential Biologics License Application (BLA) and the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new allergy treatment options for children aged 4 to 7, addressing significant market needs.
- Future Outlook: If all outstanding pre-funded warrants are exercised, total financing could reach approximately €284.5 million, further enhancing the company's competitive position in the food allergy treatment sector.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
